CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Atorvastatin +2 moredrug
Likely dose
Atorvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00728910
NCT00728910Phase 2Completed
CompareCT.gov

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

University of Pennsylvania·interventional·Posted Aug 6, 2008·Updated Feb 29, 2016

In Brief

A Phase 2 clinical trial evaluating Atorvastatin, ABT335, and 1 other intervention for Dyslipidemia. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor. It is recommended that patients who meet certain criteria for risk of heart disease take a statin medication to improve cholesterol and hopefully reduce risk of heart disease. The combination therapy will include Lipitor, Niaspan, and investigational medication (known as ABT335) in a class of drugs called fibrates. We are looking to see if and how these three medications together might improve risk factors for atherosclerosis and influence HDL cholesterol. The study will also look at the safety and any side effects that might be associated with this combination of medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
CollaboratorsAbbott

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2008
Enrollment StartJun 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.9 years ago

Interventions

Atorvastatindrug

10 mg QD for 4 weeks

ABT335drug

135 mg QD added to atorvastatin for 8 weeks

ER Niacindrug

2000 mg QD added to atorvastatin and ABT335 for 10 weeks